Eli Lilly and Co

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 43K

Market Cap: $859.4B

Website

Introduction: Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Clinical Trials

A Study of LY3502970 in Participants With Normal and Impaired Renal Function

Phase 1

Completed

Conditions: Healthy
Renal Insufficiency

Interventions: Drug: LY3502970

First Posted Date: 2023-07-07

Last Posted Date: 2024-04-23

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 24

Registration Number: NCT05936138

Locations: 🇺🇸
Clinical Pharmacology of Miami, Miami, Florida, United States
🇺🇸
Advanced Pharma CR, LLC, Miami, Florida, United States
🇺🇸
Alliance For multispecialty Research, LLC, Knoxville, Tennessee, United States

and more 1 locations

A Study to Compare Two Formulations of LY3819469 in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: LY3819469

First Posted Date: 2023-07-06

Last Posted Date: 2024-01-05

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 27

Registration Number: NCT05932446

Locations: 🇸🇬
Lilly Centre for Clinical Pharmacology, Singapore, Singapore

A Study of Once-Daily Oral Orforglipron (LY3502970) in Japanese Adult Participants With Obesity Disease

Phase 3

Active, not recruiting

Conditions: Obesity

Interventions: Drug: Orforglipron
Drug: Placebo

First Posted Date: 2023-07-05

Last Posted Date: 2024-08-28

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 236

Registration Number: NCT05931380

Locations: 🇯🇵
Nihonbashi Sakura Clinic, Chuo-ku, Tokyo, Japan
🇯🇵
Heishinkai Medical Group ToCROM Clinic, Shinjuku-ku, Tokyo, Japan
🇯🇵
Fukuwa Clinic, Chuo-ku, Tokyo, Japan

and more 13 locations

A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee

Phase 3

Active, not recruiting

Conditions: Obesity
Overweight
Osteo Arthritis Knee

Interventions: Drug: Retatrutide
Drug: Placebo

First Posted Date: 2023-07-05

Last Posted Date: 2024-12-06

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 405

Registration Number: NCT05931367

Locations: 🇲🇽
IMED Internal Medicine Clin Trials, Monterrey, Nuevo León, Mexico
🇺🇸
Northwestern University, Chicago, Illinois, United States
🇨🇦
Wharton Medical Clinic, Hamilton, Ontario, Canada

and more 44 locations

A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight

Phase 3

Active, not recruiting

Conditions: Obesity
Overweight
Osteoarthritis, Knee
Obstructive Sleep Apnea

Interventions: Drug: Retatrutide
Drug: Placebo

First Posted Date: 2023-07-03

Last Posted Date: 2024-12-11

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 2300

Registration Number: NCT05929066

Locations: 🇭🇺
Regia Med Kft, Szekesfehervar, Fejér, Hungary
🇲🇽
Kohler and Milstein Research S.A. de C.V., Mérida, Yucatán, Mexico
🇲🇽
Centro de Atención e Investigación Clínica, Aguascalientes, Mexico

and more 130 locations

A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight

Phase 3

Active, not recruiting

Conditions: Obstructive Sleep Apnea
Overweight
Obesity
Type 2 Diabetes

Interventions: Drug: Retatrutide
Drug: Placebo

First Posted Date: 2023-07-03

Last Posted Date: 2024-12-11

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 1000

Registration Number: NCT05929079

Locations: 🇲🇽
Kohler & Milstein Research S.A. De C.V., Mérida, Yucatán, Mexico
🇺🇸
Pinnacle Research Group, LLC, Anniston, Alabama, United States
🇺🇸
Cullman Clinical Trials, Cullman, Alabama, United States

and more 96 locations

A Study of LY3437943 in Participants With Impaired and Normal Liver Function

Phase 1

Recruiting

Conditions: Healthy
Hepatic Insufficiency

Interventions: Drug: LY3437943

First Posted Date: 2023-06-23

Last Posted Date: 2024-12-03

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 37

Registration Number: NCT05916560

Locations: 🇺🇸
Arizona Clinical Trials - Chandler, Chandler, Arizona, United States
🇺🇸
Accel Research Sites- Clinical Research Unit, DeLand, Florida, United States
🇺🇸
Advanced Pharma Clinical Research, Miami, Florida, United States

and more 2 locations

A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis

Phase 2

Recruiting

Conditions: Atopic Dermatitis

Interventions: Drug: LY3454738
Drug: Placebo

First Posted Date: 2023-06-22

Last Posted Date: 2024-12-09

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 260

Registration Number: NCT05911841

Locations: 🇨🇳
Huashan Hospital, Fudan University, Shanghai, Shanghai, China
🇵🇱
"DERMED" Centrum Medyczne Sp. z o.o., Lodz, Łódzkie, Poland
🇺🇸
Johnson Dermatology, Fort Smith, Arkansas, United States

and more 62 locations

A Study to Compare Two Formulations of LY3209590 in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: LY3209590 (Formulation 1)
Drug: LY3209590 (Formulation 2)

First Posted Date: 2023-06-22

Last Posted Date: 2024-04-23

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 67

Registration Number: NCT05914688

Locations: 🇸🇬
Lilly Centre for Clinical Pharmacology, Singapore, Singapore

A Drug Drug Interaction (DDI) Study of Selpercatinib (LY3527723) and Rosuvastatin in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Rosuvastatin
Drug: Selpercatinib

First Posted Date: 2023-06-18

Last Posted Date: 2024-01-05

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 32

Registration Number: NCT05906836

Locations: 🇺🇸
Labcorp Clinical Research LP, Dallas, Texas, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy